MOA Life Plus
Korea - YonginBiotechnology
Focus: MOA Life Plus is a newly founded (2024) Korean biotechnology company headquartered in Yongin, specializing in mucosal immunity medicine with a focus on neurology applications.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
5
Should You Work at MOA Life Plus?
AI assessmentMOA Life Plus is a speculative, very early-stage opportunity suited only for risk-tolerant scientists willing to bet on an unproven platform and team with minimal public track record.
Why Work Here
- Ground-floor opportunity at a newly established biotech with a novel mucosal immunity platform in an underexplored therapeutic space.
- Early-stage company allows direct impact on scientific direction and potential equity upside for founding-phase hires.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MOA Life Plus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.